Bone Morphogenetic Proteins and its Receptors; Therapeutic Targets in Cancer Progression and Bone Metastasis?

Author(s): Jeroen T. Buijs, Maj Petersen, Geertje van der Horst, Gabri van der Pluijm

Journal Name: Current Pharmaceutical Design

Volume 16 , Issue 11 , 2010

Become EABM
Become Reviewer


Breast and prostate cancer are osteotropic cancers, i.e., carcinomas that have a special predilection to form bone metastases. At postmortem examination, ∼70% of patients dying of these cancers have evidence of metastatic bone disease. Bone Morphogenetic Proteins (BMPs) were first identified by their ability to induce ectopic bone formation in vivo. Since prostate cancer cells express several BMPs, BMPs have been implicated in the osteoblastic phenotype of bone metastases. In addition to their osteogenic function, BMPs turned out to be multifunctional proteins regulating cell growth, differentiation, migration, and apoptosis in various target cells, including breast and prostate cancer cells. Especially in the last decade, studies have focused on the role of several BMPs in osteotropic cancers. In this review, the role of BMPs, particularly that of BMP7, in breast and prostate cancer will be discussed.

Keywords: Breast cancer, prostate cancer, bone morphogenetic protein, BMP, BMP7, TGF-β, epithelial-to-mesenchymal transition, bone metastasis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [1291 - 1300]
Pages: 10
DOI: 10.2174/138161210791033987
Price: $65

Article Metrics

PDF: 19